- Colorectal cancer (CRC) remains the third leading cause of cancer-related deaths in the United States and nearly 50% of patients will experience metastases during their lives.
- Anti EGFR targeted therapy is used for treatment of metastatic colorectal cancer.
- Approximately 30-50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene.
- This mutated KRAS gene is predictive of resistance to EGFR therapies in advanced colorectal cancer.
- NCCN guidelines on colon cancer (Feb.2016) recommend that all patients with metastatic colorectal cancer should have tumor tissue genotyped for KRAS mutations.
Result reported: Positive or Negative for KRAS mutations
Lincoln Labs KRAS Mutation Analysis offers:
- Turnaround time of 7-10 days
- Our highly qualified staff is accessible for any assistance regarding the tests.
- Broad coverage by most private and public insurance.
- Formalin-fixed, paraffin-embedded (FFPE) tissues from routinely prepared small biopsies are practical and standard for KRAS mutation analysis.
- Specimens are optimally fixed in 10% neutral-buffered formalin, optimal fixation time ranges from 6 to 24 hours.
- Presence of tumor cells in the sample must be assessed by a pathologist.
- Ratio of tumor cells to normal cells is crucial for adequate mutation testing and should be provide by the pathologist.
- One H&E slide and 3-5 unstained slides (6-8microns ideal) are required for mutation testing.
ICD 10 Code:81275- KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis, variants in exon 2 (eg, codons 12 and 13)